Ontology highlight
ABSTRACT:
SUBMITTER: McKeage MJ
PROVIDER: S-EPMC3495895 | biostudies-literature | 2012 Oct
REPOSITORIES: biostudies-literature
BMC cancer 20121025
<h4>Background</h4>The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours.<h4>Methods</h4>PR-104 was administered as a one-hour intravenous infusion combined with docetaxel 60 to 75 mg/m2 on day one given with or without granulocyte colony stimulating factor (G-CSF) on day two or administrated with gemcitabine 800 mg/m2 on days one ...[more]